Disease relevance of Eldepryl

• The selective monoamine oxidase (MAO) B inhibitor L-deprenyl (Eldepryl, Jumex, Movergan, Selegiline) has gained acceptance as a useful form of adjunctive therapy in the treatment of Parkinson's disease [1].
• Due to these properties Jumex may be used for the prevention, moderation of motion sickness, one of the widespread phenomena of our age, without decreasing working capacity [2].

High impact information on Eldepryl

• Selegiline hydrochloride (Eldepryl) is a monoamine oxidase-B inhibitor with antioxidant properties [3].
• Acute asthma precipitated by accidental inhalation of sodium bicarbonate granules (Carbex) [4].
• RESULTS: Intraperitoneal administration of MPTP 30 mg/kg could induce nigral apoptosis, and oral use of Eldepryl prior to MPTP treatment could completely prevent the nigral apoptosis caused by MPTP [5].
• METHODS: Three groups of C57BL mice were treated with MPTP, Eldepryl plus MPTP and normal saline, respectively, for 7 days before performing TUNEL (terminal deoxyneucleotidyl transferase-mediated dUTP-x nick end labeling) and FACS (fluorescence activated cell sorting) analyses of neuronal apoptosis in the substantia nigra [5].
• The bioavailability of two selegiline HCl (CAS 14611-52-0) tablet products was compared in a single-blind, single-dose, randomised, two-way, cross-over study with 25 healthy volunteers [6].

Chemical compound and disease context of Eldepryl

• We compared the results of treatment with selegiline (deprenyl, Eldepryl) in 17 patients with advanced Stage 4 Parkinson Disease (PD) who were on levodopa (as Sinemet) with 65 Stage 2 or 3 patients with early PD who were also on levodopa [7].

Biological context of Eldepryl

• Inhalation of Carbex [8].

References